Disease relevance of californium

• An assessment of RBE of Californium-252 for C57-Black/6 mouse fibrosarcoma by a precise afterloading technique [1].
• Feasibility study: results of treatment of primary and recurrent adenocarcinoma of the corpus uteri with californium-252 [2].
• Fifty-six patients with malignant glioma were treated with implantation of the neutron-emitting element californium-252 (252Cf) within 2 weeks after surgical debulking of the tumor [3].
• Dietary nucleosides and nucleotides do not affect tumor incidence but reduce amyloidosis incidence in B6C3F1 mice irradiated with californium-252 [4].
• Early changes in flow cytometric DNA profiles induced by californium-252 neutron brachytherapy in squamocellular carcinomas of the uterine cervix [5].

High impact information on californium

• Efficacy of brachytherapy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: single-institution study [6].
• A feasibility trial of californium-252 neutron brachytherapy combined with fractionated cobalt-60 therapy for advanced but localized stage T4 tonsillar-retromolar carcinoma is described [7].
• The relative simplicity of the glycolipid combined with the application of a mild methylation procedure and californium-252 plasma desorption mass spectrometry allowed recognition of three such acyl residues on the 3-, 4-, and 6-hydroxyl positions of the terminal glucosyl residue of the trehalose unit [8].
• The effectiveness of neutrons from a Californium-252 source in the induction of various abnormalities in the Tradescantia clone 4430 stamen hair cells (Trad-SH assay) were studied [9].
• Chromosome aberration of human peripheral blood lymphocytes exposed to californium-252 (252Cf) neutrons transmitted through a 15 cm thick iron block was analysed [10].

Biological context of californium

• The individual glucosides have been identified by californium-252 plasma desorption mass spectrometry, occasionally supplemented by hydrolysis and analysis of the liberated sugars and aglycones [11].
• Construction of storage, remote afterloader, and treatment facility for californium-252 medical sources, and radiation protection survey [12].
• Two californium-252 inhalation cases [13].
• Preliminary observations on californium-252 behaviour in sea water, sediments and zooplankton [14].
• The potential of californium-252 in radiotherapy. Preclinical measurements in physics and radiobiology [15].

Anatomical context of californium

• Californium-252 plasma desorption mass spectrometry (252Cf PDMS) of a crude, desalted, extract of piscine endocrine pancreas provided mass information for the major biologically active peptide hormones present in this tissue [16].
• Phase I-II clinical trial of Californium-252. Treatment of stage IB carcinoma of the cervix [17].

Associations of californium with other chemical compounds

• This pilot study demonstrated that use of more intense californium-252 sources, which are commonly available, would provide a method that is competitive with the ethylenediaminetetraacetic acid titration method in precision and in other aspects as well [18].
• A 3.5-micrograms californium-252 source was used for the activation, and the induced aluminum-28 and magnesium-27 activity was simultaneously measured by sodium iodide crystal gamma-ray spectrometry using dual single-channel analyzers and scalers [18].
• The product of hydrolysis, phosphatidic acid (PA), was purified by thin-layer chromatography and analyzed using californium-252 plasma desorption mass spectrometry [19].

Gene context of californium

• Letter: Beta emission from encapsulated sources of californium-252 [20].
• METHODS: Five-week-old male B6C3F1 mice were fed AIN-76B Purified Diet supplemented with NS for 1 wk and 13 mo before and after irradiation of neutron with californium-252 ((252)Cf); specifically NS was added to the AIN-76B Purified Diet (without nucleotide) to obtain a final concentration of 0%, 0.5%, or 2.5% NS [4].
• The University of Kentucky Brain Tumor Study and Research Group has developed a new treatment protocol of interstitial brain brachytherapy using Californium-252 neutron source implantation in 1980 [21].

Analytical, diagnostic and therapeutic context of californium

• Sequence determination of protected oligodeoxyribonucleotides containing phosphotriester linkages by californium-252 plasma desorption mass spectrometry [22].
• Californium-252 plasma desorption mass spectrometry (PDMS) has been employed for the characterization of a series of human insulin derivatives in order to evaluate the performance of this technique as an analytical tool in protein engineering [23].
• Intracavitary Californium-252 combined with whole-pelvis photon radiotherapy was tested as the sole form of treatment for 22 patients with Stage IB carcinoma of the cervix [17].
• Development of apparatus to measure calcium changes in the forearm and spine by neutron activation analysis using californium-252 [24].
• Separation of the components of commercial digitonin using high-performance liquid chromatography and centrifugal countercurrent chromatography. Identification of the products by californium-252 plasma desorption mass spectrometry [11].

References